Clinical Trial

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

Study acronym: POTENTIAL-M
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-03.
Status change: Not Yet Recruiting → Recruiting 2026-01-28
Trial Details
NCT Number NCT07114367
Lead Sponsor NOBO Medicine
Conditions Non Hodgkin Lymphoma (NHL)
Enrollment 9 participants
Start Date 2025-12-02
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30